Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 9/20 | 0.47 |
| ▸ | LTC4S | Q16873 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236562 | 0.87 | LTC4S (0.49) | VNN1LTC4SCA1CA2 | |
| SCHEMBL238194 | 0.86 | LTC4S (0.47) | P4HTMLTC4SMAPT | |
| SCHEMBL560557 | 0.86 | VNN1 (0.43) | VNN1MAPTCA1CA2HDAC1 | |
| SCHEMBL240031 | 0.83 | LTC4S (0.42) | LTC4S | |
| SCHEMBL27830985 | 0.81 | P4HTM (0.47) | P4HTMVNN1LTC4SHDAC1 | |
| SCHEMBL229858 | 0.81 | MAPT (0.47) | P4HTMVNN1MAPTCA1CA2 | |
| SCHEMBL236387 | 0.78 | LTC4S (0.66) | LTC4S | |
| SCHEMBL240030 | 0.78 | LTC4S (0.42) | P4HTMLTC4S | |
| SCHEMBL239257 | 0.78 | P4HTM (0.47) | P4HTMVNN1LTC4SPPARA | |
| SCHEMBL238390 | 0.78 | MAPT (0.41) | LTC4SMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429994-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120035217-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-02-09 | — | — | US | disclosed |
| EP-2406223-A2 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-01-18 | — | — | EP | disclosed |
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2011-12-29 | — | — | US | disclosed |
| WO-2010103297-A2 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | BIOLIPOX AB (SE) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103283-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | BIOLIPOX AB (SE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035217-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | P4HTM 578/4885VNN1 492/4885LTC4S 1/4885 |
| US-20120004244-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | P4HTM 403/4885VNN1 479/4885LTC4S 1/4885 |
| US-20110319431-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | P4HTM 745/4885VNN1 502/4885LTC4S 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.